Cancer Family
Anaplastic Malignant Neoplasm
CI-CAN-00000065Explore in graph →
546 active trials4 approved drugs57 evidence items
- NCIt
- C36025
Loading cancer entity…
Cancer Family
CI-CAN-00000065Explore in graph →
Clinical trials
2,019 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (323)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03405792 | Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)(2-THE-TOP) | active not recruiting | Phase 2 | 40 | University of FloridaOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT05139277 | Evaluation of the CONVIVO System | recruiting | N/A | 30 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT01535911 | Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors(Ketones) | active not recruiting | N/A | 16 | Michigan State UniversityOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03048240 | INtraoperative photoDYnamic Therapy of GliOblastoma(INDYGO) | completed | N/A | 10 | University Hospital, LilleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07391215 | 5G-PEARL: Paxalisib in Malignant Brain Tumours(5G-PEARL) | recruiting | Phase 1 / Phase 2 | 64 | Institute of Cancer Research, United KingdomOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03389230 | Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma | active not recruiting | Phase 1 | 29 | City of Hope Medical CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05653622 | Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma(SIB-DOPA) | recruiting | Phase 2 | 75 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05653635 | Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study(ReciDOPA) | recruiting | Phase 2 | 54 | Centre Paul StraussOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05756985 | Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | recruiting | — | 120 | Baptist Health South FloridaOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT07385846 | Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency | not yet recruiting | Phase 1 | 8 | Jennifer LeddonOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT05683808 | Venous Thromboembolism Prevention in Outpatients With Glioma(VTE-POG) | recruiting | Phase 2 | 40 | University of Vermont Medical CenterOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07368283 | Limited Target Volume Radiotherapy After Glioblastoma Surgery | not yet recruiting | N/A | 79 | Jiangxi Provincial Cancer HospitalOTHER | 0 | Jan 30, 2026 | clinicaltrials |
| NCT01199562 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant | active not recruiting | — | 153 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03251027 | Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma | active not recruiting | N/A | 100 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT04752813 | A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB) | active not recruiting | Phase 2 | 50 | BPGbioINDUSTRY | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07365280 | Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma | not yet recruiting | Phase 2 | 78 | ZSky Biotech IncINDUSTRY | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07366892 | Leica Microsystems Sponsored PMCF Study to Collect and Confirm Clinical Data on the Performance of the GLOW400 Device When Used in Accordance With Its Intended Use(IMED-GLOW400) | not yet recruiting | — | 37 | Leica Microsystems (Schweiz) AGINDUSTRY | 2 | Jan 26, 2026 | clinicaltrials |
| NCT04216329 | Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2026 | clinicaltrials |
| NCT04825275 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial | terminated | Early Phase 1 | 7 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07364786 | Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma(AFGBMBiop) | recruiting | Phase 2 | 10 | Peter SiesjöOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT05084430 | Study of Pembrolizumab and M032 (NSC 733972) | recruiting | Phase 1 / Phase 2 | 28 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07143812 | A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 | 10 | CHA UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours(5G-RUBY) | recruiting | Phase 1 / Phase 2 | 182 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04440358 | Exablate Blood-Brain Barrier Disruption With Carboplatin for the Treatment of rGBM | completed | Phase 1 / Phase 2 | 13 | InSightecINDUSTRY | 3 | Jan 20, 2026 | clinicaltrials |
| NCT06105619 | A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). | active not recruiting | Phase 2 / Phase 3 | 84 | Beijing Pearl Biotechnology Limited Liability CompanyINDUSTRY | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06625684 | Key Longitudinal Associations With Risk and Glioblastoma Outcomes(Key LARGO) | recruiting | — | 200 | Duke UniversityOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT03144167 | Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy(SPECTROBEVA) | recruiting | N/A | 170 | Centre Hospitalier Universitaire, AmiensOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT07347210 | Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma(MATVAC-1) | not yet recruiting | Phase 2 | 98 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04220970 | Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry | recruiting | — | 150 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jan 14, 2026 | clinicaltrials |
| NCT05465954 | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | recruiting | Phase 2 | 54 | Mayo ClinicOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT05083754 | Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma | recruiting | Phase 1 | 50 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05106296 | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | recruiting | Phase 1 | 37 | Theodore S. JohnsonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05669820 | Antisecretory Factor Glioblastoma Phase 2(AFGB2) | recruiting | Phase 2 / Phase 3 | 300 | Peter SiesjöOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06095375 | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients(REGOMA-2) | completed | Phase 1 | 21 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04049669 | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | active not recruiting | Phase 2 | 130 | Theodore S. JohnsonOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04221503 | Niraparib/TTFields in GBM | active not recruiting | Phase 2 | 30 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT03743662 | Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma | active not recruiting | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04869449 | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | terminated | Early Phase 1 | 1 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT02617745 | Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid(GLIOPLAK) | completed | Phase 2 | 244 | Centre Henri BecquerelOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04959500 | Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06717295 | The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling(CCANED-CIPHER) | recruiting | — | 6,000 | Javier ToledoINDUSTRY | 3 | Jan 2, 2026 | clinicaltrials |
| NCT07093814 | A Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma | recruiting | Phase 1 / Phase 2 | 42 | Guangzhou Virotech Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 2, 2026 | clinicaltrials |
| NCT02709226 | Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05267106 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations(FIGHT-209) | terminated | Phase 2 | 83 | Incyte CorporationINDUSTRY | 9 | Dec 30, 2025 | clinicaltrials |
| NCT06645808 | PET-imaging of Two Vartumabs in Patients With Solid Tumors(VARTUTRACE) | recruiting | Early Phase 1 | 32 | Var2 PharmaceuticalsINDUSTRY | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04474353 | Study of Tumor Treating Fields With Hypofractionated Chemoradiotherapy in Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Stanford UniversityOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05735171 | Supramarginal Resection in Glioblastoma Guided by Artificial Intelligence(SupraGlio-AI) | completed | N/A | 20 | Hospital del Rio HortegaOTHER | 1 | Dec 24, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 6, 2026source: clinicaltrials